FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
SYNGENE
629.9
+16.4 (2.67%)
Updated 03:28 28/07 IST
SYNGENE Buy or Sell - FrontPage Forums
2 Users have submitted 2 trade ideas of Rs. 112,624.5 for SYNGENE
Disclaimer100% Bullish
0% Bearish
SYNGENE Buy or Sell - Brokerage Reports
No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
635
Consensus Potential
3.39%
SYNGENE Ratings
Long term SYNGENE rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (1 Ratings)
Find answers to all your questions on live SYNGENE message board: Is SYNGENE buy or sell? Should I buy SYNGENE shares? Why are SYNGENE shares falling? Should I invest in SYNGENE stock?
- Home
- SYNGENE Forum
SYNGENE Share Price Discussion
N
Reputation: 15,707 • Yesterday 3:36 AM
Margin performance in line with expectations: Jonathan Hunt, Syngene
"Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter."
"Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter."
The Economic Times
Like
Reply
N
Reputation: 15,707 • Jul 23 4:46 AM
Sell Syngene International, target price Rs 515: Yes Securities
Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 25160.00 Crore) operating in Pharmaceuticals sector.
Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 25160.00 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Reply
N
Reputation: 3,596 • Jul 21 1:47 AM
#SYNGENE executed a 5-year agreement with #IAVI for HIV drug
#BHARTIARTL and #Intel announce collaboration to accelerate 5G in India
#NuvocoVistas Corporation gets #SEBI approval to float Rs. 5000 crore IPO
1
Reply
N
Reputation: 15,707 • Jul 21 6:06 AM
Syngene International Q1 results: Net profit rises 33% to Rs 77 cr; John Shaw to step down from board
Consolidated revenue from operations of the company stood at Rs 594.5 crore for the quarter under consideration. It was Rs 421.6 crore for the same period a year ago.
Consolidated revenue from operations of the company stood at Rs 594.5 crore for the quarter under consideration. It was Rs 421.6 crore for the same period a year ago.
The Economic Times
1
Reply
S
Reputation: 2,008 • Jul 21 2:45 AM
1
Reply
S
Reputation: 647 • Jul 21 10:53 AM
#SYNGENE Q1 : Net Profit Down 52 % To Rs 77.3 cr (QOQ), up 33 % YOY
Revenue Down 10 % To Rs 594 cr (QOQ), Up 41 % YOY
Like
Reply
S
Reputation: 3,324 • Jul 16 6:03 AM
3
Reply
S
Reputation: 3,324 • Jul 15 5:25 AM
Shivansh in SYNGENE#SYNGENE Volumes were dry But should not go bel...
#SYNGENE 606
2
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
SYNGENE Share Price - Technicals
- NewsBotYesterday 3:36 AMMargin performance in line with expectations: Jonathan Hunt, SyngeneThe Economic TimesNewsBotJul 23 4:46 AMSell Syngene International, target price Rs 515: Yes SecuritiesThe Economic TimesNewsBotJul 21 6:06 AMSyngene International Q1 results: Net profit rises 33% to Rs 77 cr; John Shaw to step down from boardThe Economic TimesNewsBotApr 30 6:21 AM
Sell Syngene International, target price Rs 400: Yes SecuritiesThe Economic TimesNewsBotApr 29 2:46 AM
Discovery, development, dedicated centres and manufacturing biz contribute to Syngene growth: Jonathan HuntThe Economic TimesNewsBotMar 9 2:23 AM
Neutral UPL; Target Of Rs 631: Motilal OswalMoneycontrolNewsBotFeb 8 9:58 AM
Buy UPL; Target Of Rs 632: SharekhanMoneycontrolNewsBotFeb 5 8:58 AM
Accumulate UPL; Target Of Rs 601: Prabhudas LilladherMoneycontrolNewsBotFeb 4 10:53 AM
Accumulate UPL; Target Of Rs 609: Dolat Capital MarketMoneycontrolNewsBotFeb 4 10:53 AM
Neutral UPL; Target Of Rs 574: Motilal OswalMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.